文献速递胸部肿瘤

不适合III期同步放化疗的非小细胞肺癌患者单纯放疗后度伐利尤单抗治疗的2期试验:SPIRAL-RT研究

A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study.
PubMed 文献 · Eur J Cancer · 2023-10-22

这项在日本开展的单臂、前瞻性、开放标签、多中心2期试验纳入33例不适合同步放化疗的III期非小细胞肺癌患者,给予单纯放疗(54-66 Gy)后度伐利尤单抗(10 mg/kg 每2周,最长12个月)治疗。1年无进展生存率为39.1%(90%CI 24.7-54.6%),客观缓解率42.4%(95%CI 27.2-59.2%),中位无进展生存期8.9个月(95%CI 7.4-19.4),中位总生存期20.8个月(95%CI 15.8-不可估计)。结论认为度伐利尤单抗在单纯放疗后对不适合同步放化疗的III期NSCLC患者有效且毒性可耐受。

要点

  • 不适合同步放化疗的III期NSCLC患者单纯放疗后度伐利尤单抗1年PFS率为39.1%(90%CI 24.7-54.6%)。
  • 客观缓解率42.4%(95%CI 27.2-59.2%),中位PFS 8.9个月,中位OS 20.8个月。
  • 最常见不良事件为放射性肺炎(51.5%),仅30.3%(10/33)患者完成1年度伐利尤单抗治疗。

核心结论

  • 度伐利尤单抗在单纯放疗后对不适合同步放化疗的III期NSCLC患者是有效治疗且毒性可耐受。

研究设计与样本

  • 单臂、前瞻性、开放标签、多中心2期试验,在日本开展。
  • 2019年9月至2021年4月从8家机构入组33例患者,中位年龄79岁,男性占78.8%,3例(9.1%)体力状况评分为2。
  • 患者接受放疗(54-66 Gy)后度伐利尤单抗10 mg/kg 每2周,最长12个月。
  • 主要终点为1年无进展生存率,次要终点为客观缓解率、无进展生存期、总生存期和安全性。

主要发现

  • 1年无进展生存率为39.1%(90%CI 24.7-54.6%)。
  • 客观缓解率为42.4%(95%CI 27.2-59.2%)。
  • 中位无进展生存期为8.9个月(95%CI 7.4-19.4),中位总生存期为20.8个月(95%CI 15.8-不可估计)。
  • 最常见不良事件为放射性肺炎(51.5%)。
  • 度伐利尤单抗中位治疗时间为6.4个月(范围0.50-12.0),至终点时30.3%(10/33)患者完成1年度伐利尤单抗治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although concurrent chemoradiotherapy (CCRT) followed by durvalumab is the standard treatment for patients with stage III non-small cell lung cancer (NSCLC), only half of the patients are allowed to receive CCRT in real-world settings. We evaluated the efficacy and safety of durvalumab after radiation monotherapy for NSCLC patients who are ineligible for chemoradiotherapy. METHODS: A single-arm, prospective, open-label, multicenter phase II trial was conducted in Japan. The patients received radiation (54-66 Gy) followed by durvalumab (10 mg/kg every 2 weeks for up to 12 months). The primary endpoint was the 1-year progression-free survival (PFS) rate. The secondary endpoints were the objective response rate (ORR), PFS, overall survival (OS), and safety. RESULTS: Between September 2019 and April 2021, 33 patients were enroled from eight institutions. The median patient age was 79 years, and the majority of patients were male (78.8%). The 1-year PFS rate was 39.1% (90% confidence interval [CI]: 24.7-54.6%). Three patients (9.1%) had a performance status of 2. The ORR was 42.4% (95% CI: 27.2-59.2%). The median PFS and OS were 8.9 (95% CI: 7.4-19.4) and 20.8 (95% CI: 15.8-not estimable) months, respectively. The most common adverse event was radiation pneumonitis (51.5%). The median treatment duration was 6.4 (range: 0.50-12.0) months for durvalumab. At the endpoint, 30.3% (10/33) of the patients had completed 1 year of durvalumab therapy. CONCLUSIONS: Durvalumab is an effective treatment with tolerable toxicity following radiation monotherapy in stage III NSCLC patients who are ineligible for chemoradiotherapy. TRIAL REGISTRATION: JMA-IIA00434 (jRCT).

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Yamada T, Goto Y, Tanaka H, et al. A phase 2 trial of durvalumab treatment following radiation monotherapy in patients with non-small cell lung cancer ineligible for stage III chemoradiotherapy: The SPIRAL-RT study. Eur J Cancer. 2023. PMID: 37890349. doi:10.1016/j.ejca.2023.113373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。